|
C19ORF55 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6972000027593E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.84699999984073E-07 |
| Normal-vs-Stage2 |
1.004040E-04 |
| Normal-vs-Stage3 |
3.36640000320187E-08 |
| Normal-vs-Stage4 |
1.5978699999919E-05 |
| Stage1-vs-Stage2 |
9.904600E-01 |
| Stage1-vs-Stage3 |
3.796600E-01 |
| Stage1-vs-Stage4 |
7.523000E-01 |
| Stage2-vs-Stage3 |
5.468000E-01 |
| Stage2-vs-Stage4 |
8.216400E-01 |
| Stage3-vs-Stage4 |
7.078400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.89639999984104E-07 |
| Normal-vs-AfricanAmerican |
4.723900E-02 |
| Normal-vs-Asian |
3.99509999999825E-05 |
| Caucasian-vs-AfricanAmerican |
1.480380E-01 |
| Caucasian-vs-Asian |
9.896000E-01 |
| AfricanAmerican-vs-Asian |
1.296800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.11830000043756E-07 |
| Normal-vs-Female |
6.19590000416892E-08 |
| Male-vs-Female |
9.564000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.29930000092315E-08 |
| Normal-vs-Age(41-60Yrs) |
2.06649999999753E-05 |
| Normal-vs-Age(61-80Yrs) |
1.03360000003327E-07 |
| Normal-vs-Age(81-100Yrs) |
3.556000E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.369400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.247000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.542000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.633400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.303600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.561600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.782040E-03 |
| Classical-VS-Follicular |
2.530400E-01 |
| Classical-VS-Other |
2.308000E-01 |
| Classical-VS-Normal |
1.87816999999146E-05 |
| Tall-VS-Follicular |
2.385200E-01 |
| Tall-VS-Other |
8.970600E-01 |
| Tall-VS-Normal |
1.6525000035017E-08 |
| Follicular-VS-Other |
7.209200E-01 |
| Follicular-VS-Normal |
4.01220000000313E-05 |
| Other-VS-Normal |
8.715800E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.38129999660563E-08 |
| Normal-vs-N1 |
2.27050000001228E-06 |
| N0-vs-N1 |
7.898600E-01 |
|
|
